0000899243-21-002081.txt : 20210114
0000899243-21-002081.hdr.sgml : 20210114
20210114175400
ACCESSION NUMBER: 0000899243-21-002081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210112
FILED AS OF DATE: 20210114
DATE AS OF CHANGE: 20210114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P.
CENTRAL INDEX KEY: 0001691428
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 21529928
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P.
CENTRAL INDEX KEY: 0001721036
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 21529929
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC
CENTRAL INDEX KEY: 0001721035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 21529930
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management LP
CENTRAL INDEX KEY: 0001687078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 21529931
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Management, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-12
0
0001789972
Cullinan Management, Inc.
CGEM
0001691428
UBS Oncology Impact Fund L.P.
UBS TRUSTEES (CAYMAN) LTD
5TH FL CAYMAN CORP CENTER 27 HOSPITAL
GEORGE TOWN
E9
KY1-1106
CAYMAN ISLANDS
0
0
1
0
0001721036
Oncology Impact Fund (Cayman) Management L.P.
UBS TRUSTEES (CAYMAN) LTD
5TH FL CAYMAN CORP CENTER 27 HOSPITAL
GEORGE TOWN
E9
KY1-1106
CAYMAN ISLANDS
0
0
1
0
0001721035
MPM Oncology Impact Management GP LLC
C/O MPM ASSET MANAGEMENT LLC
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001687078
MPM Oncology Impact Management LP
C/O MPM ASSET MANAGEMENT LLC
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2021-01-12
4
C
0
1136525
A
1136525
D
Common Stock
2021-01-12
4
C
0
3551640
A
4688165
D
Common Stock
2021-01-12
4
C
0
2276692
A
6964857
D
Common Stock
2021-01-12
4
C
0
649030
A
7613887
D
Common Stock
2021-01-12
4
P
0
300000
21.00
A
7913887
D
Series Seed Convertible Preferred Stock
2021-01-12
4
C
0
1136525
D
Common Stock
1136525
0
D
Series A Convertible Preferred Stock
2021-01-12
4
C
0
3551640
D
Common Stock
3551640
0
D
Series B Convertible Preferred Stock
2021-01-12
4
C
0
2276692
D
Common Stock
2276692
0
D
Series C Convertible Preferred Stock
2021-01-12
4
C
0
649030
D
Common Stock
649030
0
D
Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.
Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering.
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P
2021-01-14
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.
2021-01-14
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC
2021-01-14
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP
2021-01-14